Please Wait...

Bioclinica™ Acquires Tourtellotte Solutions

– Adds Depth to eClinical Services with Supply Chain Simulation and Parameter-Driven Interactive Voice and Web Response Technology (IXR) –

September 16, 2009

BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired privately-held Tourtellotte Solutions, Inc. (Tourtellotte), a leader in software and services for the bio-pharmaceutical industry. 

Tourtellotte, headquartered in Wayland, MA and with additional operations in Bhubaneswar, India, provides cutting edge software applications and consulting services which support pharmaceutical development.  In 2001, Tourtellotte pioneered the first major parameter-driven IVR and the world’s first IWR for a top five global pharmaceutical company.  The software they designed and have continued to modify and support is currently being used in over 150 active clinical trials and has been used in over 300 trials since its inception.  In 2007, Tourtellotte introduced tcVisualize, a product which allows biopharmaceutical companies to simulate and optimize the clinical supply chain. Using tcVisualize, study managers can develop the perfect clinical supply plan resulting in a rapid return on investment by reducing product waste, trial delays, and lost patient enrollment due to product stockouts. tcVisualize is currently being used by four of the top ten global pharmaceutical companies.

Process knowledge and expertise in IVR/IWR, simulation and forecasting, and clinical supplies combined with other Tourtellotte innovations, has led to the development of Trident, a next-generation interactive voice/interactive web response system (IXR) that redefines how interactive response technology can function in the biopharmaceutical industry.  It is parameter-driven, built specifically for the web, and is able to support rapid, flexible customization that supplies greater control over cost and data than traditional IVR.

“Tourtellotte brings a leading edge technology platform and a proven development and support team to BioClinica. These additions expand the ways in which we can work with our global biopharmaceutical clients to improve the overall clinical trial process,” said Mark Weinstein, President and CEO of BioClinica.  “Ed Tourtellotte, President of Tourtellotte Solutions, will be joining BioClinica as Vice President – Product Innovation and he and his team will be part of our eClinical Division, reporting to Peter Benton.”

“When we looked at strategies to rapidly grow and expand the company to meet the demand for our products, joining the BioClinica team was the logical step,” said Ed Tourtellotte, President of Tourtellotte Solutions. “BioClinica has a strong global presence in the market, robust product offerings and great client relationships.  Their experienced sales and operations infrastructure will enable the benefits of clinical trial supply optimization and the next generation of IXR to reach more new clients, faster.  We look forward to being an integral part of BioClinica’s continued success.”

Mr. Weinstein concluded, “The acquisition of Tourtellotte further demonstrates how BioClinica is executing on our strategy of adding complementary products that deliver more efficient clinical trials.  Tourtellotte Solutions embraces many of the same tenets that have yielded success for BioClinica’s clients over the past twenty years, and we welcome them to our team.”

BioClinica is purchasing substantially all of the assets of Tourtellotte for $2.1 million in cash at closing plus additional payments based upon achieving certain milestones.  If certain predetermined milestones are achieved an additional $3.2M in cash and 350,000 shares of BioClinica common stock can be earned.

Tourtellotte generated approximately $3.9 million in revenue in 2008. BioClinica estimates that Tourtellotte will generate approximately $5.0 million in revenue for the full year 2009 on a stand-alone basis. BioClinica currently estimates that for the remaining three and a half months of 2009, Tourtellotte will contribute approximately $1.2 million in revenue and contribute a small amount of operating income and be EPS neutral. The above unaudited financial information is based upon preliminary estimates, subject to the company’s further review.

Excel Partners, LLC acted as exclusive financial advisor to BioClinica in this transaction and Covington Associates, LLC acted as exclusive financial advisor to Tourtellotte.

About Bioclinica

Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.




Media Contact
Nicole Klatsky
+1 (609) 865-5212

Learn more about Bioclinica at and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.


Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a…
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour…
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff…
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app…
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin…
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.…
Bioclinica (4 weeks ago)